Clinical Trial Detail

NCT ID NCT02132754
Title Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

Therapies

Pembrolizumab

MK-4166

Age Groups: adult

No variant requirements are available.